Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations

Anticancer Research

Volumn 20, Issue 4, 2000, Pages 2537-2539

  Smith, Martin L ^a   Seo, Young R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; Cyclin E; Taxol

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN E; PACLITAXEL;

APOPTOSIS; ARTICLE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; CISPLATIN; CYCLIN E; HUMANS; PACLITAXEL; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033855754     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Keyomarsi K, Conte D, Toyofuku W and Fox MP: Deregulation of cyclin E in breast cancer. Oncogene 11: 941-950, 1995.
2. Dou QP, Pardee AB and Keyomarsi K: Cyclin E- a better prognostic marker for breast cancer than cyclin D? Nat Med 2: 254, 1996.
3. Molendini L, Benassi M, Magagnoli G, Merli M, Sollazzo M, Ragazzini P, Gamberi G, Ferrari C, Balladelli A, Bacchini P and Picci P: Prognostic significance of cyclin expression in human osteosarcomas. Int J Oncol 12: 1007-1011, 1998.
4. Session DR, Lee GS, Choi J, and Wolgemuth DJ: Expression of cyclin E in gynecologic malignancies. Gynecol Oncol 72: 32-37, 1999.
5. Quade BJ, Park JJ, Crum CP, Sun D and Dutta, A: In vivo cyclin E expression as a marker for early cervical neoplasia. Mod Pathol 11: 1238-1246, 1998.
6. Eguchi N, Fujii K, Tsuchida A, Yamamoto S, Sasaki T and Kajiyama, G: Cyclin E overexpression in human gallbladder carcinomas. Oncol Rep 6: 93-96, 1999.
7. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E and Klimstra DS: Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 59: 2470-2476, 1999.
8. Spruck CH, Won KA and Reed SI: Deregulated cyclin E induces chromosome instability. Nature 401: 297-300, 1999.
9. Smith ML, Kontny HU, Bortnick R and Fornace, AJ Jr: The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Exp Cell Res 230: 61-68, 1997.
10. Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Deng Q Hanawalt PC and Fornace AJ Jr: Involvement of the p53 pathway in nucleotide excision repair: DNA repair responses to UV-radiation or cisplatin in mouse embryo fibroblasts lacking p53, p21, and/or gadd45 genes. Mol. Cell Biol 20: 3105-3114, 2000.
11. Smith ML, Chen I-T, Zhan Q, O'Connor PM and Fomace, AJ Jr: Involvement of the p53 tumor suppressor in repair of UV-type DNA damage. Oncogene 10: 1053-1059, 1995.
12. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fomace AJ and O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
13. Smith ML: Mdm2 sensitizes MCF7 breast cancer cells to cisplatin or carboplatin. Breast Cancer Res Treat 1560: 1-7, 1999.
14. Nielsen NH, Emdin SO, Cajander J and Landberg G: Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 14: 295-304, 1997.
15. Scott KA and Walker RA: Lack of cyclin E immunoreactivity in nonmalignant breast and association with proliferation in breast cancer. Br J Cancer 76: 1288-1292, 1997.
16. Bortner DM and Rosenberg MP: Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 17: 453-459, 1997.
17. Eltabbakh GH, Piver MS, Hempling RE, Redo FO, Lele SB, Marchetti DL, Baker TR and Blumenson LE: Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol 70: 392-397, 1998.
18. Gibb RK, Taylor DD, Wan T, O'Connor DM, Doering DL and Gercel-Taylor C: Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol 65: 13-22, 1997.